The combination of atezolizumab, an inhibitor of programmed death-ligand 1 (PD-L1), and bevacizumab, an anti-vascular endothelial growth factor (VEGF) agent, shows therapeutic promise for hepatocellular carcinoma (HCC) [1]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.